Oramed Insider Trades: COO’s Back‑to‑Back Sale & Buy Signal Strategic Shift

Corporate News Report

Insider Activity Highlights a Strategic Shift at Oramed

On July 1, 2026, Hexter Joshua, Oramed’s Chief Operating Officer and Chief Business Officer, executed a Rule 10b‑5 transaction in which he sold 137,000 shares of Oramed common stock at a weighted‑average price of $4.46 per share. The following day, he purchased 50,000 shares at $3.69 per share, well below the then‑current market price of $4.60. The simultaneous sale and subsequent purchase represent a back‑to‑back pattern that signals a tactical rebalancing rather than a panic divestiture.

Impact on Joshua’s Holdings

Joshua’s holdings decreased from 1,160,384 shares to 1,023,384 shares after the July 1 sale, indicating a modest divestiture while retaining a substantial stake in the company. This activity underscores continued confidence in Oramed’s long‑term prospects, particularly in its oral‑delivery platform that has recently advanced through critical pre‑clinical stages and entered phase 1 human trials.

Market Context

The sale occurred just after Oramed posted a 27.78 % monthly gain and a 112.96 % year‑to‑date rally. The liquidity event is therefore unlikely to depress the stock’s momentum. The subsequent purchase at a lower price provides a small hedging opportunity, reinforcing Joshua’s overall position.

The market’s reaction has been largely neutral, with a sentiment score of +43 and a chatter index of 76.72 %, typical for insider trades of this magnitude. Analysts should monitor for future clustering of trades by Joshua or other executives, as such patterns can presage upcoming product milestones or regulatory approvals that justify the price trajectory.

Insider Trading Profile

Joshua’s transaction history reveals a disciplined, structured approach:

• March 2026: Purchased 95,889 shares twice in a single filing, boosting his holding to 1,160,384 shares.
• January 2026: Sold 19,000 performance‑stock units and purchased an equal amount of common stock, reflecting a reliance on vesting‑based compensation.
• July 2, 2026: Exercised a 50,000‑share stock‑option sale in equal 6,250‑share installments, balancing risk and reward while preserving liquidity.

Overall, Joshua’s insider activity demonstrates a long‑term commitment to Oramed, coupled with periodic portfolio adjustments aligned with the company’s cash‑flow and valuation cycles.

Broader Insider Activity

Other key insiders have also been active:

• CFO Gabay Avraham sold 73,360 shares on July 1, 2026 at $4.51 per share.
• CEO Kidron Nadav sold 44,000 shares on the same day, consistent with executive‑level liquidity management.

These trades, while larger in absolute terms, do not currently undermine confidence. The combined insider activity reflects a company in a growth phase, managing compensation and cash needs while maintaining substantial ownership stakes in management.

Implications for Investors

For portfolio managers and institutional investors, Joshua’s recent sell‑buy pattern offers a low‑impact liquidity event with clear strategic intent: to rebalance holdings while maintaining a long‑term interest in Oramed’s innovative platform. The modest decrease in ownership coupled with a subsequent purchase suggests that executives view the company’s valuation favorably and anticipate continued upside.

Future Rule 10b‑5 filings, option‑exercise dates, and clinical‑trial milestones will provide early signals of Oramed’s performance trajectory and could inform timing decisions for larger institutional positions.

Transaction Summary